Medtronic plc (MDT)
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic plc NYSE: MDT is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases an aging population suffers.
Billionaire Ray Dalio's Former Hedge Fund Is Buying These 3 Top Dividend Stocks. Should You?
Billionaire Ray Dalio's former hedge fund has recently invested in three top dividend stocks. ExxonMobil, Medtronic, and Microsoft all offer attractive dividend profiles.
Medtronic plc (MDT) 2024 Wells Fargo Healthcare Conference
Medtronic plc (NYSE:MDT ) 2024 Wells Fargo Healthcare Conference September 4, 2024 11:35 AM ET Company Participants Geoff Martha - Chairman & CEO Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Good afternoon or good morning, and it's about to be good afternoon and welcome to the 2024 Wells Fargo Healthcare Conference. Thank you for helping make this our largest healthcare conference yet.
Is Medtronic Stock a Buy?
Medtronic hasn't been growing its sales at an impressive clip of late. However, one of the company's segments looks increasingly promising.
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year.
Medtronic: Is The Company Back?
Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic remains undervalued with solid competitive advantages and a promising dividend streak. The company's focus on innovation, strong market position, and dividend growth potential make it a long-term buy for conservative investors.
Diabetes and Neuro Products Ignite Medtronic's Q1 Earnings Rally
Shares of medical device manufacturer Medtronic PLC NYSE: MDT are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal 2025, which ended July 26, could help to drive renewed upward momentum. Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.
What's Next For Medtronic Stock After An Upbeat Q1?
Medtronic (NYSE: MDT) recently reported its Q1 fiscal 2025 results (fiscal ends in April), with revenues and earnings exceeding our estimates. The company reported revenue of $7.9 billion and adjusted earnings of $1.23 per share, compared to our estimates of $7.9 billion and $1.21, respectively.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics (Revised)
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
Demand for Medtronic's Medical Devices Lifts Profit and Sales
Medtronic (MDT) shares advanced in intraday trading Tuesday as the medical technology firm posted better-than-expected results and raised its guidance on strong demand for its medical devices.
